MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PHILPOT, R. M.
Right arrow Articles by HODGSON, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PHILPOT, R. M.
Right arrow Articles by HODGSON, E.

Molecular Pharmacology, Vol 8, 204-214, Copyright © 1972 by the American Society for Pharmacology and Experimental Therapeutics

The Effect of Piperonyl Butoxide Concentration on the Formation of Cytochrome P-450 Difference Spectra in Hepatic Microsomes From Mice

RICHARD M. PHILPOT 1 and ERNEST HODGSON 1

1 Department of Entomology, North Carolina State University, Raleigh, North Carolina 27607

A direct relationship is observed between the formation of the piperonyl butoxide-reduced cytochrome P-450 double Soret difference spectrum (type III) and inhibition of the formation of the carbon monoxide—cytochrome P-450 difference spectrum. This relationship appears to involve a single binding site..

The type III piperonyl butoxide—cytochrome P-450 interaction exerts a similar effect on the formation of the carbon monoxide-, pyridine-, n-octylamine-, and ethyl isocyanide— cytochrome P-450 difference spectra. Inhibition of the formation of the spectrum produce by (+)-benzphetamine is greater than that observed with the other ligands.

The relationship between the change in absorbance and the change in absorbance divided by substrate concentration is linear for the formation of the type III spectrum produced by piperonyl butoxide, inhibition by the latter of the formation of the spectrum produced by carbon monoxide, and formation of the pyridine type II substrate spectrum at low pyridine concentrations. At high pyridine concentrations and with (+)-benzphetamine this relationship is curvilinear.

The piperonyl butoxide type III interaction does not inhibit the formation of the pyridine type II substrate spectrum at low pyridine concentrations. At high pyridine concentrations the inhibition observed is similar to the inhibition of the (+)-benzphetamine type I substrate spectrum.

Our observations suggest that piperonyl butoxide binds to one form of cytochrome P-450 at a single site and that an additional form of the cytochrome is present in noninduced hepatic microsomes from mice, which does not bind type I substrates or form a type III interaction with piperonyl butoxide.

Submitted on September 14, 1971







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1972 by the American Society for Pharmacology and Experimental Therapeutics